One area in which March proved to be a busy month was in Board appointments, where both Boards of Directors and Advisory Boards saw a number of interesting additions.
Two senior officials at the FDA's drug promotion office have resigned, leading to speculation that a clampdown on some advertising may be on the way.
Roche will spend $50bn on manufacturing and R&D facilities in the US, with a pledge to export more medicines from the US than it imports.
Tariffs on US pharma imports could remove discounts offered to health systems by biosimilars and threaten the future of the sector, says a non-profit.
A complaint against GSK alleging a major breach of the pharma industry's code of practice on prescribing information has been upheld by the PMCPA.
Editor's Picks
